comparemela.com

Latest Breaking News On - Nasdaq stockholm small - Page 8 : comparemela.com

Saniona AB: Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases

Saniona AB: Saniona publishes its Annual Report for 2020

Saniona AB: Saniona publishes its Annual Report for 2020 that the English version of the Annual R , Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 This information was submitted for publication, through the agency of the contact persons set out above, at 17.55 About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory

Notice of Saniona AB annual shareholders meeting

Notice of Saniona AB annual shareholders meeting April 23, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders meeting ( Sw . In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has resolved that the annual shareholders meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means that the annual shareholders meeting will be conducted without the physical presence of shareholders, proxies or external parties and that shareholders exercise of voting rights at the annual shareholders meeting can only take place by advance shareholders voting in the order prescribed below. Information on the resolutions passed by the annual shareholders meeting wi

Saniona AB: Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021

Saniona AB: Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021 April 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021. SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, K Ca3.1. This ion channel is found in immune cells and fibroblasts, and it controls the proliferation, migration and release of cytokines and collagen. Previous studies have indicated that K

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.